NASDAQ:ALLO - Allogene Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $27.28 +1.32 (+5.08 %) (As of 03/22/2019 03:03 AM ET)Previous Close$25.96Today's Range$25.83 - $27.5052-Week Range$21.67 - $35.55Volume359,000 shsAverage Volume403,227 shsMarket Capitalization$3.31 billionP/E Ratio-4.15Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California. Receive ALLO News and Ratings via Email Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLO Previous Symbol CUSIPN/A CIKN/A Webwww.allogene.com Phone650-457-2700Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio-4.15 Forward P/E Ratio-13.31 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees122 Outstanding Shares121,483,000Market Cap$3.31 billion Next Earnings Date6/14/2019 (Estimated) OptionableNot Optionable Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions What is Allogene Therapeutics' stock symbol? Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO." How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics Inc (NASDAQ:ALLO) released its quarterly earnings results on Friday, March, 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.10. View Allogene Therapeutics' Earnings History. When is Allogene Therapeutics' next earnings date? Allogene Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, June 14th 2019. View Earnings Estimates for Allogene Therapeutics. What price target have analysts set for ALLO? 6 brokers have issued 12-month price objectives for Allogene Therapeutics' shares. Their forecasts range from $29.00 to $41.00. On average, they anticipate Allogene Therapeutics' stock price to reach $35.25 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. View Analyst Price Targets for Allogene Therapeutics. What is the consensus analysts' recommendation for Allogene Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allogene Therapeutics. What are Wall Street analysts saying about Allogene Therapeutics stock? Here are some recent quotes from research analysts about Allogene Therapeutics stock: 1. According to Zacks Investment Research, "Allogene Therapeutics, Inc. is a biotechnology company. It develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. The company's product pipeline consists of UCART19, ALLO-501, ALLO-715, ALLO-819, CD70, DLL3 and ALLO-647 which are in clinical stage. Allogene Therapeutics, Inc. is headquartered in South San Francisco, California. " (3/18/2019) 2. William Blair analysts commented, "Allogene Therapeutics, Inc. Just as We are initiating coverage on Outperform rating and $37 fair value estimate. As noted in our sector landscape piece, “Off the The Next Step for Cell Therapy,” we believe that the next phase of growth in the widespread utilization of cell therapies will be catalyzed by the successful development of “off the shelf” modalities. We therefore view Allogene as a core holding for investors looking for exposure to innovation in this subsector with de- risked initial targets and indications." (3/13/2019) 3. JPMorgan Chase & Co. analysts commented, "Allogenes’s first earnings call as a public company was fairly uneventful. The company announced detailed information on the Phase 1 trial design for ALLO 501 that was more or less in line with our expectations. Bigger picture, we believe that ALLO is well positioned in the allogeneic CAR T space and that these approaches may be the next chapter in the evolution of CAR T therapies, opening up this modality to a wider patient population. That said, after a strong post-IPO run, we remain on the sidelines given the early stage of ALLO’s proprietary programs and few value inflecting catalysts anticipated before 2020." (3/11/2019) 4. Cowen Inc analysts commented, "Tuesday, Synlogic reported 4Q results and reviewed recent progress. Management reiterated plans to present topline results from ongoing Phase 1/2 trials of by mid-year, which could establish POC in patients with hyperammonemia and phenylketonuria (PKU), respectively. While these trials utilize bacterial slurry formulations, management indicated future trials would use pill-based formulations. While the transition may require clinical bridging studies, we view the new formulations as essential for commercial viability. If the SYNB1020 demonstrates a meaningful impact on serum ammonia, next steps could include a trial in urea cycle disorders (UCD), an indication with an established biomarker-based registrational endpoint. With $123M in cash, we believe Synlogic has adequate resources to sustain operations through 2020. $15 PT." (3/8/2019) Has Allogene Therapeutics been receiving favorable news coverage? Media coverage about ALLO stock has been trending somewhat negative on Friday, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allogene Therapeutics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next few days. Who are some of Allogene Therapeutics' key competitors? Some companies that are related to Allogene Therapeutics include Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Denali Therapeutics (DNLI) and Aerie Pharmaceuticals (AERI). What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include AbbVie (ABBV), Biogen (BIIB), Pfizer (PFE), QUALCOMM (QCOM), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), argenx (ARGX), Gilead Sciences (GILD), Allergan (AGN) and BioMarin Pharmaceutical (BMRN). Who are Allogene Therapeutics' key executives? Allogene Therapeutics' management team includes the folowing people: Mr. Joshua A. Kazam, Co-Founder & Director (Age 42)Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 70)Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 59)Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51)Dr. Alison Moore Ph.D., Chief Technical Officer (Age 52) When did Allogene Therapeutics IPO? (ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO. When does Allogene Therapeutics' lock-up period expire? Allogene Therapeutics' lock-up period expires on Tuesday, April 9th. Allogene Therapeutics had issued 18,000,000 shares in its public offering on October 11th. The total size of the offering was $324,000,000 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period. Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include VV Manager LLC (6.32%), FMR LLC (4.04%), BlackRock Inc. (1.71%), Perceptive Advisors LLC (1.27%), venBio Select Advisor LLC (0.93%) and Jennison Associates LLC (0.68%). Company insiders that own Allogene Therapeutics stock include Arie Belldegrun, David D Chang and Group Holdings (Sbs) Advis Tpg. View Institutional Ownership Trends for Allogene Therapeutics. Which institutional investors are buying Allogene Therapeutics stock? ALLO stock was acquired by a variety of institutional investors in the last quarter, including VV Manager LLC, FMR LLC, BlackRock Inc., Perceptive Advisors LLC, venBio Select Advisor LLC, Jennison Associates LLC, Partner Fund Management L.P. and Lord Abbett & CO. LLC. Company insiders that have bought Allogene Therapeutics stock in the last two years include Arie Belldegrun, David D Chang and Group Holdings (Sbs) Advis Tpg. View Insider Buying and Selling for Allogene Therapeutics. How do I buy shares of Allogene Therapeutics? Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Allogene Therapeutics' stock price today? One share of ALLO stock can currently be purchased for approximately $27.28. How big of a company is Allogene Therapeutics? Allogene Therapeutics has a market capitalization of $3.31 billion. Allogene Therapeutics employs 122 workers across the globe. What is Allogene Therapeutics' official website? The official website for Allogene Therapeutics is http://www.allogene.com. How can I contact Allogene Therapeutics? Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected] MarketBeat Community Rating for Allogene Therapeutics (NASDAQ ALLO)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 102 (Vote Outperform)Underperform Votes: 124 (Vote Underperform)Total Votes: 226MarketBeat's community ratings are surveys of what our community members think about Allogene Therapeutics and other stocks. Vote "Outperform" if you believe ALLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALLO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: Why is the LIBOR significant?